Cited 22 times in
Cost-effectiveness of bevacizumab-based therapy versus cisplatin plus pemetrexed for the first-line treatment of advanced non-squamous NSCLC in Korea and Taiwan
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김주항 | - |
dc.date.accessioned | 2014-12-20T17:34:54Z | - |
dc.date.available | 2014-12-20T17:34:54Z | - |
dc.date.issued | 2011 | - |
dc.identifier.issn | 1743-7555 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/94871 | - |
dc.description.abstract | AIMS: The aim of this analysis is to investigate the mean incremental costs and life expectancy associated with two first-line treatments for advanced non-squamous non-small cell lung cancer (NSCLC) in Korea and Taiwan; bevacizumab plus cisplatin and gemcitabine (BevCG) and cisplatin plus pemetrexed (CP). METHODS: A health economic (area under curve) model with three health states was developed to assess health outcomes (life-years gained [LYG]), direct costs, and incremental cost-effectiveness ratio (ICER). Progression-free survival (PFS) and overall survival (OS) were derived from randomized clinical trials and used in an indirect comparison in order to estimate their cost effectiveness. A life-time horizon was used. Costs and outcomes were discounted yearly by 5% in Korea and by 3% in Taiwan. RESULTS: The incremental LYG for the BevCG patients compared with patients treated with CP were 1.10 (13.2 months) in Korea and 1.19 (14.3 months) in Taiwan. The incremental costs were 37,439,968 ($ 33,322) in Korea and NT$ 1,910,615 ($ 64,541) in Taiwan. The incremental cost-effectiveness ratio was 34,064,835 ($ 30,318) in Korea and NT$ 1,607,960 ($ 54,317) in Taiwan. The inputs tested in one-way sensitivity analyses had very little impact on the overall cost effectiveness. CONCLUSION: This analysis shows that BevCG is more costly but is also associated with additional life-years in Korea and Taiwan. The ICER per LYG suggests that BevCG is a cost-effective therapy when compared to CP for patients with advanced NSCLC in Korea and Taiwan. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 22~33 | - |
dc.relation.isPartOf | ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antibodies, Monoclonal/administration & dosage | - |
dc.subject.MESH | Antibodies, Monoclonal/economics* | - |
dc.subject.MESH | Antibodies, Monoclonal/therapeutic use* | - |
dc.subject.MESH | Antibodies, Monoclonal, Humanized | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/economics* | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.MESH | Bevacizumab | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung/drug therapy* | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung/economics | - |
dc.subject.MESH | Cisplatin/administration & dosage | - |
dc.subject.MESH | Cost-Benefit Analysis | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Glutamates/administration & dosage | - |
dc.subject.MESH | Guanine/administration & dosage | - |
dc.subject.MESH | Guanine/analogs & derivatives | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Korea | - |
dc.subject.MESH | Lung Neoplasms/drug therapy* | - |
dc.subject.MESH | Lung Neoplasms/economics | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Pemetrexed | - |
dc.subject.MESH | Survival Analysis | - |
dc.subject.MESH | Taiwan | - |
dc.title | Cost-effectiveness of bevacizumab-based therapy versus cisplatin plus pemetrexed for the first-line treatment of advanced non-squamous NSCLC in Korea and Taiwan | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Myung-Ju AHN | - |
dc.contributor.googleauthor | Chun-Ming TSAI | - |
dc.contributor.googleauthor | Te-Chun HSIA | - |
dc.contributor.googleauthor | Elaine WRIGHT | - |
dc.contributor.googleauthor | John Wen-Cheng CHANG | - |
dc.contributor.googleauthor | Heung Tae KIM | - |
dc.contributor.googleauthor | Joo-Hang KIM | - |
dc.contributor.googleauthor | Jin Hyoung KANG | - |
dc.contributor.googleauthor | Sang-We KIM | - |
dc.contributor.googleauthor | Eun-Jin BAE | - |
dc.contributor.googleauthor | Mijeong KANG | - |
dc.contributor.googleauthor | Johanna LISTER | - |
dc.contributor.googleauthor | Stefan WALZER | - |
dc.identifier.doi | 10.1111/j.1743-7563.2011.01399.x | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00945 | - |
dc.relation.journalcode | J00257 | - |
dc.identifier.eissn | 1743-7563 | - |
dc.identifier.pmid | 21585705 | - |
dc.identifier.url | http://onlinelibrary.wiley.com/doi/10.1111/j.1743-7563.2011.01399.x/abstract | - |
dc.subject.keyword | antineoplastic combined chemotherapy protocol | - |
dc.subject.keyword | Asia | - |
dc.subject.keyword | bevacizumab | - |
dc.subject.keyword | cost‐benefit analysis | - |
dc.subject.keyword | non‐small cell lung carcinoma | - |
dc.contributor.alternativeName | Kim, Joo Hang | - |
dc.contributor.affiliatedAuthor | Kim, Joo Hang | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 7 | - |
dc.citation.number | Suppl. 2 | - |
dc.citation.startPage | 22 | - |
dc.citation.endPage | 33 | - |
dc.identifier.bibliographicCitation | ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol.7(Suppl. 2) : 22-33, 2011 | - |
dc.identifier.rimsid | 27815 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.